Designing advanced and cost-effective electrocatalytic system for nitric oxide(NO)reduction reaction(NORR)is vital for sustainable NH_(3) production and NO removal,yet it is a challenging task.Herein,it is shown that ...Designing advanced and cost-effective electrocatalytic system for nitric oxide(NO)reduction reaction(NORR)is vital for sustainable NH_(3) production and NO removal,yet it is a challenging task.Herein,it is shown that phosphorus(P)-doped titania(TiO_(2))nanotubes can be adopted as highly efficient catalyst for NORR.The catalyst demonstrates impressive performance in ionic liquid(IL)-based electrolyte with a remarkable high Faradaic efficiency of 89%and NH3 yield rate of 425μg·h^(−1)·mg_(cat).^(−1),being close to the best-reported results.Noteworthy,the obtained performance metrics are significantly larger than those for N_(2) reduction reaction.It also shows good durability with negligible activity decay even after 10 cycles.Theoretical simulations reveal that the introduction of P dopants tunes the electronic structure of Ti active sites,thereby enhancing the NO adsorption and facilitating the desorption of ^(*)NH_(3).Moreover,the utilization of IL further suppresses the competitive hydrogen evolution reaction.This study highlights the advantage of the catalyst−electrolyte engineering strategy for producing NH_(3) at a high efficiency and rate.展开更多
Up to know,product information for COVID-19 mRNA vaccines do not include their use in patients receiving immunosuppressive medication,since they were not included in trials(1).For the BNT162b2 mRNA vaccine,one case of...Up to know,product information for COVID-19 mRNA vaccines do not include their use in patients receiving immunosuppressive medication,since they were not included in trials(1).For the BNT162b2 mRNA vaccine,one case of otherwise totally asymptomatic elevations of alanine aminotransferase(ALT),aspartate aminotransferase(AST),alkaline phosphatase(ALP)andγ-glutamyl transpeptidase(GGT)serum concentrations in a liver transplant recipient has been reported after the first injection(2).In the present retrospective study,we present safety outcomes of COVID-19 vaccinations in 56 liver transplant patients from two Chinese centers vaccinated with the domestic PiCoVacc,BBIBP-CorV and ZF2001 vaccines.Thirty vaccinated physicians from the Hepatopancreatobiliary Center of Beijing Tsinghua Changgung Hospital served as control,from which 1 participant received an Ad5-nCoV vaccine.The study deadline was 2021-10-31.The observation period for adverse reactions,such as muscle pain and fatigue was 1 week,while for laboratory examinations such as liver function the follow-up period was 1 month.展开更多
基金financially supported by the National Natural Science Foundation of China(Grant Nos.22075211,21601136,and 21905246)the Key Projects of Zhejiang Natural Science Foundation(Grant No.LZ20E010001).
文摘Designing advanced and cost-effective electrocatalytic system for nitric oxide(NO)reduction reaction(NORR)is vital for sustainable NH_(3) production and NO removal,yet it is a challenging task.Herein,it is shown that phosphorus(P)-doped titania(TiO_(2))nanotubes can be adopted as highly efficient catalyst for NORR.The catalyst demonstrates impressive performance in ionic liquid(IL)-based electrolyte with a remarkable high Faradaic efficiency of 89%and NH3 yield rate of 425μg·h^(−1)·mg_(cat).^(−1),being close to the best-reported results.Noteworthy,the obtained performance metrics are significantly larger than those for N_(2) reduction reaction.It also shows good durability with negligible activity decay even after 10 cycles.Theoretical simulations reveal that the introduction of P dopants tunes the electronic structure of Ti active sites,thereby enhancing the NO adsorption and facilitating the desorption of ^(*)NH_(3).Moreover,the utilization of IL further suppresses the competitive hydrogen evolution reaction.This study highlights the advantage of the catalyst−electrolyte engineering strategy for producing NH_(3) at a high efficiency and rate.
基金supported by the National Science&Technology Major Project[grant No.2017ZX100203205]National Natural Science Foundation of China[grant No.81930119]funders had no role in design of the study and collection,analysis,and interpretation of data and in writing the manuscript.
文摘Up to know,product information for COVID-19 mRNA vaccines do not include their use in patients receiving immunosuppressive medication,since they were not included in trials(1).For the BNT162b2 mRNA vaccine,one case of otherwise totally asymptomatic elevations of alanine aminotransferase(ALT),aspartate aminotransferase(AST),alkaline phosphatase(ALP)andγ-glutamyl transpeptidase(GGT)serum concentrations in a liver transplant recipient has been reported after the first injection(2).In the present retrospective study,we present safety outcomes of COVID-19 vaccinations in 56 liver transplant patients from two Chinese centers vaccinated with the domestic PiCoVacc,BBIBP-CorV and ZF2001 vaccines.Thirty vaccinated physicians from the Hepatopancreatobiliary Center of Beijing Tsinghua Changgung Hospital served as control,from which 1 participant received an Ad5-nCoV vaccine.The study deadline was 2021-10-31.The observation period for adverse reactions,such as muscle pain and fatigue was 1 week,while for laboratory examinations such as liver function the follow-up period was 1 month.
